Disparity in Guideline‐Based Antidiabetic Drugs Prescribing for Type 2 Diabetes Patients in Primary Healthcare Facilities Across China, 2017–2019
Pharmacoepidemiology and Drug Safety · 2024
DOI: 10.1002/pds.5882 ↗Kurz gefasst
Leitlinie in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2024. Verfasst von Mengyuan Fu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Primary Health Care, Practice Patterns, Physicians'. Die Arbeit nennt 39 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Purpose
The purpose of this study is to evaluate the pattern, appropriateness, and cost of antidiabetic drugs prescribed for patients with Type 2 diabetes at primary healthcare facilities (PHFs) in China.
Methods
We collected outpatient‐visit prescriptions from 363 PHFs in 31 cities covering eastern, central, and western regions of China. The visits of adult patients with Type 2 diabetes diagnosis were collected and classified the antidiabetic medication pattern of each patient use as recommended or non‐recommended according to Chinese guidelines. We then calculated the proportion of guideline‐recommended patterns and the average monthly cost for each pattern, overall and by region.
Results
Of 33 519 prescriptions for Type 2 diabetes, most (73.9%) were for guideline‐recommended antidiabetic treatments. The proportion of guideline‐recommended prescriptions varied by region (eastern [75.9%], central [87.5%], and western [59.7%]). Metformin monotherapy was the most common guideline‐recommended treatment in all three regions (eastern [20.1%], central [28.0%], and western [24.6%]). The most common non‐guideline‐recommended treatments were monotherapy of insulin (eastern [16.5%], central [5.1%], and western [25.7%]) and traditional Chinese antidiabetic medicines (eastern [5.6%], central [5.7%], and western [11.1%]). The average monthly costs were lower for guideline‐recommended treatments compared to non‐recommended treatments in all regions (eastern [13.6 ± 15.4 USD vs. 28.1 ± 22.0 USD], central [9.8 ± 10.9 USD vs. 28.7 ± 19.4 USD], and western [17.9 ± 21.4 USD vs. 30.3 ± 23.6 USD]).
Conclusions
The majority of patients with Type 2 diabetes received guideline‐recommended antidiabetic medications at PHFs in China, with only half of the prescriptions containing guideline‐recommended metformin. Utilization of guideline‐recommended therapies differed across regions. Tailored interventions to promote evidence‐based antidiabetic prescribing are urgently needed, especially in the undeveloped western region.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China.
- International Research Center for Medicinal Administration, Peking University, Beijing, China.
ORCID-Profile: Mengyuan Fu, Luwen Shi, Xiaodong Guan
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Fu, M., Gong, Z., Zhu, Y., Li, C., Li, H., Shi, L., & Guan, X. (2024). Disparity in Guideline‐Based Antidiabetic Drugs Prescribing for Type 2 Diabetes Patients in Primary Healthcare Facilities Across China, 2017–2019. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.5882
Vancouver
Fu M, Gong Z, Zhu Y, Li C, Li H, Shi L, et al. Disparity in Guideline‐Based Antidiabetic Drugs Prescribing for Type 2 Diabetes Patients in Primary Healthcare Facilities Across China, 2017–2019. Pharmacoepidemiology and Drug Safety. 2024. doi:10.1002/pds.5882
BibTeX
@article{Fu2024,
author = {Fu, Mengyuan and Gong, Zhiwen and Zhu, Yuezhen and Li, Can and Li, Huangqianyu and Shi, Luwen and Guan, Xiaodong},
title = {Disparity in Guideline‐Based Antidiabetic Drugs Prescribing for Type 2 Diabetes Patients in Primary Healthcare Facilities Across China, 2017–2019},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2024},
doi = {10.1002/pds.5882}
}
EUVIMED